ES2193590T3 - Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos. - Google Patents

Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.

Info

Publication number
ES2193590T3
ES2193590T3 ES98959231T ES98959231T ES2193590T3 ES 2193590 T3 ES2193590 T3 ES 2193590T3 ES 98959231 T ES98959231 T ES 98959231T ES 98959231 T ES98959231 T ES 98959231T ES 2193590 T3 ES2193590 T3 ES 2193590T3
Authority
ES
Spain
Prior art keywords
transferasa
farnesil
procedure
preparation
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98959231T
Other languages
English (en)
Inventor
Hyun Il Lee
Jong Sung Koh
Jin Ho Lee
Won Hee Jung
You Seung Shin
Hyun Ho Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980011359A external-priority patent/KR19990066679A/ko
Priority claimed from KR1019980023698A external-priority patent/KR20000002788A/ko
Priority claimed from KR1019980046457A external-priority patent/KR20000015758A/ko
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of ES2193590T3 publication Critical patent/ES2193590T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Derivado de imidazol representado por la siguiente **fórmula** en la que n1 representa un número entero de 1 a 4, A representa hidrógeno; alquilo C1-C10 de cadena lineal o ramificada que puede estar opcionalmente sustituido por un cicloalquilo C3-C7 o un alcoxi C1- C4; o un radical seleccionado del siguiente grupo: en donde R1 y R1¿ representan, independientemente entre sí, hidrógeno, halógeno, ciano, nitro, hidroxicarbonilo, aminocarbonilo, aminotiocarbonilo, alcoxi C1-C4, fenoxi, fenilo, benciloxi o alquilo C1-C4 que puede estar opcionalmente sustituido por un cicloalquilo C3-C6.
ES98959231T 1997-11-28 1998-11-25 Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos. Expired - Lifetime ES2193590T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR19970063858 1997-11-28
KR1019980011359A KR19990066679A (ko) 1997-11-28 1998-03-31 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR1019980023698A KR20000002788A (ko) 1998-06-23 1998-06-23 피라졸 구조를 갖는 파네실 전이효소 억제제 및그의 제조방법
KR1019980024423A KR19990062439A (ko) 1997-11-28 1998-06-26 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR19980031512 1998-08-03
KR1019980046457A KR20000015758A (ko) 1998-08-03 1998-10-30 피롤 구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
PCT/KR1998/000377 WO1999028315A1 (en) 1997-11-28 1998-11-25 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof

Publications (1)

Publication Number Publication Date
ES2193590T3 true ES2193590T3 (es) 2003-11-01

Family

ID=27555104

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98959231T Expired - Lifetime ES2193590T3 (es) 1997-11-28 1998-11-25 Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.

Country Status (18)

Country Link
US (3) US6268363B1 (es)
EP (1) EP1045846B1 (es)
JP (2) JP3548118B2 (es)
CN (1) CN1188407C (es)
AR (1) AR017700A1 (es)
AT (1) ATE239014T1 (es)
AU (1) AU731272B2 (es)
BR (1) BR9815423A (es)
CA (1) CA2310629A1 (es)
DE (1) DE69814167T2 (es)
ES (1) ES2193590T3 (es)
HU (1) HUP0004238A3 (es)
ID (1) ID24175A (es)
IL (1) IL135473A0 (es)
NZ (1) NZ504013A (es)
PL (1) PL340729A1 (es)
RU (1) RU2179975C1 (es)
WO (1) WO1999028315A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058683B1 (en) * 1998-02-02 2002-12-04 Lg Chemical Limited Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
KR100395300B1 (ko) * 1999-08-11 2003-08-27 주식회사 엘지생명과학 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
WO2000064891A1 (en) * 1999-04-13 2000-11-02 Lg Chem Investment Ltd. Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
KR100412334B1 (ko) * 2000-02-22 2003-12-31 주식회사 엘지생명과학 4-치환된-1ｈ-피롤-3-카복실산 에스테르의 새로운 제조방법
US20030087949A1 (en) * 2000-03-30 2003-05-08 Mikiko Sodeoka Indolylpyrrole derivatives and cell death inhibitors
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
RU2311415C2 (ru) * 2002-08-23 2007-11-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
MXPA05006200A (es) * 2002-12-23 2005-08-19 Aventis Pharma Gmbh Derivados de pirazol como inhibidores del factor xa.
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US7214825B2 (en) * 2003-10-17 2007-05-08 Honeywell International Inc. O-(3-chloropropenyl) hydroxylamine free base
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US20080119456A1 (en) * 2004-05-29 2008-05-22 Trond Ulven Substituted Thiazoleacetic Acid as Crth2 Ligands
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CA2659155A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
EP2292663B1 (en) 2006-08-28 2013-10-02 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
DK3041507T3 (da) 2013-08-26 2021-07-26 Biontech Res And Development Inc Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN109890795A (zh) 2016-09-29 2019-06-14 拜耳作物科学股份公司 新的5-取代的咪唑衍生物
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
EP3694889A1 (en) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Human antibodies to thomsen-nouvelle (tn) antigen
US20230243836A1 (en) 2018-07-20 2023-08-03 Pierre Fabre Medicament Receptor for vista

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5681795A (en) * 1994-03-02 1997-10-28 Zeneca Limited 3-benzoyl pyrrole and pyrazole herbicides
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1121217C (zh) 1996-03-29 2003-09-17 特拉科斯有限公司 免疫原性组合物
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250204A1 (en) * 1996-04-03 1997-10-09 Neville J. Anthony Inhibitors of farnesyl-protein transferase
JP2000507597A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
CA2249650A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036901A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
US6472526B1 (en) 2002-10-29
JP2001524550A (ja) 2001-12-04
NZ504013A (en) 2002-02-01
JP3548118B2 (ja) 2004-07-28
AU731272B2 (en) 2001-03-29
CN1188407C (zh) 2005-02-09
RU2000116633A (ru) 2004-02-20
RU2179975C1 (ru) 2002-02-27
BR9815423A (pt) 2000-10-17
HUP0004238A3 (en) 2001-07-30
ID24175A (id) 2000-07-13
US20020137769A1 (en) 2002-09-26
CA2310629A1 (en) 1999-06-10
EP1045846A1 (en) 2000-10-25
AR017700A1 (es) 2001-09-12
PL340729A1 (en) 2001-02-26
JP2002161092A (ja) 2002-06-04
DE69814167T2 (de) 2004-02-26
AU1508399A (en) 1999-06-16
CN1279680A (zh) 2001-01-10
US6268363B1 (en) 2001-07-31
WO1999028315A1 (en) 1999-06-10
ATE239014T1 (de) 2003-05-15
IL135473A0 (en) 2001-05-20
DE69814167D1 (de) 2003-06-05
HUP0004238A2 (hu) 2001-05-28
US6518429B2 (en) 2003-02-11
EP1045846B1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
ES2193590T3 (es) Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
NO20045561L (no) 3'[(2Z)-(2-(3,4-dimetylfenyl)-1,5-dihydro-3-metyl-5-okso-41-I-pyrazol-4-yliden]hydrazin]-2'-hydroksy-(1,1'-bifenyl]-3-karboksy lsyre bis-(monoetanolamin)
DK1246809T3 (da) 5-aryl-1H-1,2,4-triazolforbindelser som inhibitor for cyclooxygenase-2 og farmaceutiske sammensætninger som indeholder dem
ATE464283T1 (de) N-substituierte p-menthancarbonsäureamide
CO6150146A2 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica
AR009212A1 (es) Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen
DK0956282T3 (da) Sulfinsyrederivater, fremgangsmåde til deres fremstilling og anvendelse
DE502004004659D1 (de) Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren
DE60045100D1 (de) Fungizide
MX9203019A (es) Derivados heterociclicos y composiciones farmaceuticas que los contienen.
DK431784A (da) Oxopyrimidin-derivater og farmaceutiske praeparater som indeholder dem
CO5040027A1 (es) Mezclas fungicidas de eteres fenilbencilicos y/o cabamatos con dinitrofenoles, procedimieto para combatir hongos dani- nos con dichas mezclas; utiliacion de dichos compuestos en la preparacion de dichas mezclas y agentes fungicidas for- mulados con d
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
CR9873A (es) Derivados de 6-heteroarilpiridoindolona, su preparacion y su aplicacion en terapeutica
CO6311082A2 (es) Derivados de sulfonil-quinolina, procesos para su preparación y composiciones farmacéuticas que los contienen
AR021114A1 (es) Procedimiento de fotoestabilizacion de filtros solares derivados de 1,3,5-triazina
ES2173829T1 (es) Procedimiento y composiciones para inhibir la polimerizacion de radicales libres en la piel y el cabello.
DK0984936T3 (da) Cyanoguanidiner som celleproliferationsinhibitorer
CO5590951A2 (es) Derivados de aminoacetonitrilo
PA8626301A1 (es) Proceso para preparar derivados de n-aril-piperazina
DK1196129T3 (da) Farmaceutiske og kosmetiske sammensætninger omfattende urocaninsyrederivater som radikalscavengers eller antioxidanter
AR006539A1 (es) Derivados de diarilmetilidenfurano, procedimiento para su preparacion y composicion farmaceutica que contiene a dichos derivados.
ES2189736T3 (es) Derivados de la benzamida y medicamentos que los contienen.
CO5040014A1 (es) Mezclas fungicidas